Flow Pharma, Inc.
Synthetic peptide vaccines in dry powder microparticle formulations for viral diseases, designed using AI-driven epitope selection
- Sector
- Biotech
- Headquarters
- WARRENSVILLE HEIGHTS, OH
- Latest Form D
- $50K, Aug 2024
- Total capital
- $4.8M
- Federal grants
- $137K
- 1 award · 2018
- Rank in peer group#15 of 1449
- Private capital raised
- $3.6M
- 4 Form D · last Aug 2024
- 27 months since last filing
- Federal contracts
- $1.0M
- 1 award · Defense
- Rank in Biotech#188 of 4373
- Granted patents
- 2
- 24 pending · first 2019
- Rank in peer group#397 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$50K
- Private capital raisedForm D · SEC · 3rd filing$180K
- Federal contractDefense · STTR Phase II$1.0M
- Federal grantDefense · Phase I · Marburg Virus Prophylactic Medical Countermeasure$137K
- Private capital raisedForm D · SEC · 2nd filing$1.1M
- Private capital raisedForm D · SEC · 1st filing$2.3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Federal grants#15 · top 1%
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Reid Michael RubsamenResearcherExecutive Officer, DirectorLinked by 1 patent · $137K in grants as PI
- Anthony Martin TufaroDirectorNamed in SEC Form D filings
- Babatunde Martin OtulanaDirectorNamed in SEC Form D filings
- Charles Vincent HerstExecutive OfficerNamed in SEC Form D filings
- Gil Martin Van BokkelenExecutive OfficerNamed in SEC Form D filings
- Lester J LloydExecutive Officer, DirectorNamed in SEC Form D filings
Show all 12 people
- Pamela Vincent SteeleDirectorNamed in SEC Form D filings
- Stephen Martin FarrDirectorNamed in SEC Form D filings
- Thomas Martin BarnishExecutive OfficerNamed in SEC Form D filings
- Thomas John BradyExecutive OfficerNamed in SEC Form D filings
- Tikoes Martin BlankenbergDirectorNamed in SEC Form D filings
- Tom Martin BradyExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 26- GrantedControlled Release Of Antibodies To Modulate CytokinesUSPTOUS 12,729,237
- PendingMicrosphere Formulations Comprising Multiple Non-identical Peptides And Methods For Making The SameUSPTOApplication 18550416
- PendingMethod Of Making A Personalized Cancer VaccineUSPTOApplication 18953764
Show all 26 patent records
- Controlled Release Of Antibodies To Modulate CytokinesSep 8, 2026 · US 12,729,237Granted
- Microsphere Formulations Comprising Multiple Non-identical Peptides And Methods For Making The SameAug 28, 2025 · Application 18550416Pending
- Method Of Making A Personalized Cancer VaccineMay 15, 2025 · Application 18953764Pending
- Vaccine For SARS-COV-2Oct 31, 2024 · Application 18287771Pending
- Controlled Release Of Antibodies To Modulate CytokinesSep 23, 2021 · Application 17202770Pending
- Patient Personalized Cancer VaccineSep 3, 2020 · Application 16806674Pending
- Method Of Making A Personalized Cancer VaccineSep 3, 2020 · Application 16806664Pending
- Peptide Particle FormulationApr 11, 2019 · Application 16216744Pending
- Peptide Particle FormulationJan 8, 2019 · US 10,172,936Granted
- Vaccine Formulation Of Mannose Coated Peptide ParticlesMay 14, 2015 · Application 14601849Pending
- Adjuvant And Antigen Particle FormulationApr 17, 2014 · Application 13826804Pending
- Peptide Particle FormulationJun 6, 2013 · Application 13691234Pending
- Design, Manufacture, And Use Of Personalized Cancer VaccinesApplication PCTUS2020020458Pending
- Design, Manufacture, And Use Of Personalized Cancer VaccinesApplication 62812723Pending
- Vaccine For SARS-COV-2Application PCTUS2022071869Pending
- Adjuvant And Antigen Particle FormulationApplication PCTUS2014024443Pending
- Controlled Release Vaginal Gel With Antiviral ParticlesApplication PCTUS2014022338Pending
- Controlled Release Vaginal Gel With Antiviral ParticlesApplication 61783357Pending
- Peptide Particle FormulationApplication PCTUS2012067408Pending
- Vaccine Formulation Of Mannose Coated Peptide ParticlesApplication PCTUS2012028779Pending
- Peptide Particle FormulationApplication PCTUS2011039278Pending
- SILTUXIMAB IL-6 BLOCKING ANIBODIES TO TREAT SARS-CoV-2Application 62992136Pending
- Microsphere Formulations Comprising Multiple Non-identical Peptides And Methods For Making The SameApplication PCTUS2022071868Pending
- Micro-encapsulated Encapulsated Formulations Of IL-6 Blocking Anibodies To Treat Corona Virus Infection Disease (COVID-19)Application 62991456Pending
- Controlled Release Of Antibodies To Modulate CytokinApplication 63041617Pending
- Injectable Formulation Of Poly(lactic-co-glycolic (plga)) Microspheres Encapsulating SiltuximabApplication PCTUS2021022512Pending
Related companies, and why
- Molecular Loop Biosciences, Inc.Similar federal contract value in Biotech · $1M in contracts
- OXFORD BIOMEDICAL RESEARCH, INC.Similar federal contract value in Biotech · $1M in contracts
- Gliknik IncSimilar federal contract value in Biotech · $1M in contracts
- SPACE TANGO LLCSimilar federal contract value in Biotech · $998K in contracts
- DIANT PHARMA INCSimilar federal contract value in Biotech · $995K in contracts
- LUCIGEN CORPORATIONSimilar federal contract value in Biotech · $994K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .